Earnings summaries and quarterly performance for Neumora Therapeutics.
Executive leadership at Neumora Therapeutics.
Board of directors at Neumora Therapeutics.
Research analysts who have asked questions during Neumora Therapeutics earnings calls.
DT
Douglas Tsao
H.C. Wainwright & Co.
4 questions for NMRA
Also covers: ALKS, APLS, ARGX +19 more
Brian Abrahams
RBC Capital Markets
3 questions for NMRA
Also covers: ACAD, ATAI, BCRX +17 more
Graig Suvannavejh
Mizuho Securities
3 questions for NMRA
Also covers: ADAP, ADVM, ALEC +11 more
MM
Myles Minter
William Blair & Company
3 questions for NMRA
Also covers: ALEC, ARCT, ARGX +11 more
Yatin Suneja
Guggenheim Partners
3 questions for NMRA
Also covers: ACAD, ARGX, AXSM +10 more
Ami Fadia
Needham & Company, LLC
2 questions for NMRA
Also covers: ACAD, ALKS, AVDL +10 more
Paul Matteis
Stifel
2 questions for NMRA
Also covers: ABOS, ACAD, ALKS +11 more
Tessa Romero
JPMorgan Chase & Co.
2 questions for NMRA
Also covers: ACAD, AGIO, CYTK +5 more
Chen Yang
Bank of America
1 question for NMRA
Also covers: AMLX, CVAC
HG
Hanxing Gao
Guggenheim Partners
1 question for NMRA
JB
John Boyle
William Blair & Company
1 question for NMRA
Also covers: VTGN
JP
Julian Pino
Jefferies
1 question for NMRA
Also covers: ACAD, ALEC, ALNY +2 more
PK
Poorna Kannan
Needham & Company
1 question for NMRA
Also covers: AXSM, RVMD
Recent press releases and 8-K filings for NMRA.
Neumora Therapeutics, Inc. Provides Corporate Presentation and Announces Key Milestones
NMRA
New Projects/Investments
Guidance Update
- Neumora Therapeutics, Inc. (NMRA) reported a cash runway extending into the third quarter of 2027.
- The company anticipates multiple key milestones in 2026 across its Metabolic Disease, Neurogenerative Disease, and Neuropsychiatric Disease franchises, including topline data readouts and clinical program initiations.
- In its Phase 1b study for Agitation in Alzheimer’s Disease, NMRA-511 demonstrated a clinically meaningful reduction in CMAI total score and an unsurpassed clinical effect size in patients with elevated anxiety, with a favorable tolerability and safety profile.
- Preclinical studies of NMRA-215 for obesity showed up to 19% weight loss as monotherapy and up to 26% in combination therapy, with a clinical program expected to initiate in 1H 2026 and human proof-of-concept data anticipated around the end of 2026.
Jan 12, 2026, 12:00 PM
Neumora Reports Positive Phase IB Data for NMRA-511 in Alzheimer's Disease Agitation
NMRA
New Projects/Investments
Guidance Update
- Neumora Therapeutics reported positive top-line data from its Phase IB Signal-Seeking Study of NMRA-511 for Alzheimer's disease agitation, demonstrating a compelling effect size that supports further development.
- NMRA-511 achieved a clinically meaningful reduction in CMAI total score of 15.7 points at week eight in the modified analysis set and an unrivaled effect size of a 20.1-point absolute reduction in patients with elevated anxiety. The drug also showed a favorable safety and tolerability profile, with a low 2.5% discontinuation rate due to adverse events and no observed sedation or somnolence.
- The company plans to initiate a MAD extension cohort and transition to a once-daily extended-release formulation for NMRA-511 in 2026, which is expected to extend market exclusivity into 2046. A Phase II/III study is planned thereafter.
- Neumora also provided updates on other pipeline programs, including an increased enrollment size for navacaprant studies with top-line results expected in Q2 2026, and the clinical initiation for NMRA-215 moved to the first half of 2026, with proof of concept data anticipated by year-end 2026.
Jan 5, 2026, 1:00 PM
Neumora Announces Positive Phase 1b Data for NMRA-511 in Alzheimer's Disease Agitation
NMRA
New Projects/Investments
- Neumora announced positive top-line data from its Phase 1b signal-seeking study of NMRA-511 for Alzheimer's disease agitation.
- The study demonstrated a favorable safety and tolerability profile with a low discontinuation rate of 2.5% and no observed sedation or somnolence.
- NMRA-511 showed a clinically meaningful reduction in CMAI total score, with an absolute reduction of 15.7 points and a Cohen's d effect size of 0.2 to 0.23 in the modified analysis set.
- In patients with elevated anxiety, NMRA-511 achieved an unprecedented effect size, with a 20.1-point absolute reduction in CMAI total score and a Cohen's d effect size of 0.51 to 0.64 at week eight.
- Neumora plans to initiate a MAD extension cohort in 2026 to evaluate higher doses and transition to a once-daily extended-release formulation in 2026, which is expected to extend market exclusivity to 2046.
Jan 5, 2026, 1:00 PM
Neumora Therapeutics Announces Positive NMRA-511 Phase 1B Results for AD Agitation
NMRA
New Projects/Investments
- Neumora Therapeutics announced positive results from its Phase 1B study of NMRA-511 for agitation in Alzheimer's disease (AD).
- NMRA-511 demonstrated an effect size similar to Auvelity in the total population and an even more pronounced effect size in patients with elevated anxiety at baseline, surpassing Rexulti.
- The drug exhibited a favorable safety and tolerability profile, with typically mild to moderate adverse events and a low discontinuation rate of 2.5% due to adverse events, notably without sedation or somnolence.
- Neumora plans to initiate and complete a MAD extension cohort in 2026 to evaluate higher doses and transition to a once-daily extended-release formulation in 2026, which is expected to extend patent exclusivity until 2046.
- Following these steps, the company plans to initiate a Phase 2-3 study for NMRA-511 in AD agitation.
Jan 5, 2026, 1:00 PM
Neumora Therapeutics Announces Positive Results for NMRA-511 Phase 1b Study
NMRA
New Projects/Investments
Guidance Update
- Neumora Therapeutics, Inc. announced positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer's disease (AD) agitation.
- NMRA-511 demonstrated a clinically meaningful effect size, achieving a 15.7 reduction on mean CMAI total score, and showed an unsurpassed clinical effect size in a pre-specified population with elevated anxiety.
- The study highlighted a favorable tolerability and safety profile for NMRA-511, with no reports of somnolence or sedation.
- Neumora plans to initiate a multiple ascending dose expansion study for NMRA-511 in 2026 and expects its cash, cash equivalents, and marketable securities to support operations into the third quarter of 2027.
Jan 5, 2026, 11:44 AM
Neumora Provides Update on Clinical Pipeline and Financial Position at Stifel 2025 Healthcare Conference
NMRA
New Projects/Investments
Guidance Update
- Neumora anticipates up to six clinical readouts across its four main clinical-stage assets over the next 12 months.
- The company plans to move its NLRP3 inhibitor, NMRA-215, into the clinic in Q1 2026, aiming for human clinical proof-of-concept data in monotherapy and combination settings before the end of 2026.
- A readout for the NMRA-511 phase 1b study in Alzheimer's disease agitation is expected around the end of 2025.
- The M4 PAM franchise, including NMRA-861 (entered clinic in July 2025) and NMRA-898 (entered clinic), plans to provide an update with data from phase 1 SAD/MAD studies by the middle of 2026.
- Neumora reported over $170 million on its balance sheet at the end of Q3, providing a cash runway into 2027 to fund its operational plan and upcoming clinical catalysts.
Nov 12, 2025, 7:00 PM
Neumora Provides Updates on Clinical Pipeline and Financial Position
NMRA
New Projects/Investments
Guidance Update
- Neumora reported a balance sheet of approximately $170 million as of the end of Q3, providing a cash runway into 2027 and fully funding all highlighted clinical catalysts.
- The company anticipates six clinical readouts over the next 12 months, including data for NMRA-511 around year-end, and topline data for navacaprant's COASTAL 3 and COASTAL 2 studies in Q1 2026 and Q2 2026, respectively.
- NMRA-215, an NLRP3 inhibitor for obesity, demonstrated class-leading weight loss in DIO studies and is scheduled to begin first-in-human studies in Q1 2026, with 12-week human proof-of-concept data expected by the end of 2026.
- Neumora is advancing two M4 PAM programs, NMRA-898 and NMRA-861, into the clinic, with a franchise update planned by mid-2026.
Nov 10, 2025, 7:30 PM
Nomura Provides Updates on Pipeline Programs and Clinical Data Readouts
NMRA
New Projects/Investments
Guidance Update
- Nomura announced class-leading weight loss data for NMRA-215, its oral NLRP3 inhibitor for obesity, from diet-induced obesity studies, showing up to 19% body weight loss as monotherapy and 26% in combination with semaglutide. Phase I studies for NMRA-215 are expected to initiate in 2026.
- NMRA-898 has entered the clinic, marking a major milestone for the M4 PAM franchise for schizophrenia, with a comprehensive franchise update anticipated by mid-2026.
- Top-line data from the Phase Ib signal-seeking study for NMRA-511 in Alzheimer's disease agitation is expected around the end of 2025.
- Top-line data from the COLASTAL III and II studies for Nevacoprant are on track to be reported in the first and second quarters of 2026.
Oct 27, 2025, 12:00 PM
Neumora Therapeutics Announces Positive NMRA-215 Obesity Data and Upcoming Clinical Milestones
NMRA
New Projects/Investments
Guidance Update
- Neumora Therapeutics announced class-leading weight loss data for its oral NLRP3 inhibitor, NMRA-215, in diet-induced obesity (DIO) studies, demonstrating up to 19% body weight loss as monotherapy and 26% in combination with semaglutide.
- Phase 1 studies for NMRA-215 in obesity are expected to initiate in Q1 2026, with 12-week human proof-of-concept data anticipated in 2026.
- NMRA-898, an M4PAM candidate for schizophrenia, has entered into the clinic.
- The company expects top-line data from the Phase 1b study of NMRA-511 in Alzheimer's disease agitation around the end of 2025, and from the COASTAL-3 and -2 studies with navacaprant in Q1 and Q2 2026, respectively.
- Neumora's cash runway extends into 2027, supporting multiple value-creating catalysts over the next 12 months.
Oct 27, 2025, 12:00 PM
Neumora provides pipeline updates and announces new data for NMRA-215
NMRA
New Projects/Investments
Product Launch
Guidance Update
- Neumora announced class-leading weight loss data for its oral NLRP3 inhibitor, NMRA-215, from diet-induced obesity (DIO) studies, showing up to 19% body weight loss as monotherapy and 26% in combination with Semaglutide in DIO models. Phase I studies for NMRA-215 are expected to initiate in Q1 2026.
- Top-line data from the phase I-B signal-seeking study for NMRA-511 in Alzheimer's disease agitation is anticipated around the end of 2025.
- For Navacaprant, top-line data from the KOASTAL-3 and KOASTAL-2 studies in Major Depressive Disorder (MDD) are expected in Q1 2026 and Q2 2026, respectively.
- Neumora projects up to six distinct value-creating catalysts over the next 12 months, all supported by its cash runway guidance extending into 2027.
Oct 27, 2025, 12:00 PM
Quarterly earnings call transcripts for Neumora Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more